Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5989992 | 1.00 | CA2 (0.41) | CA2 | |
| SCHEMBL220561 | 0.80 | CA2 (0.61) | CA2 | |
| SCHEMBL220873 | 0.80 | CA2 (0.61) | CA2 | |
| SCHEMBL220562 | 0.80 | CA2 (0.61) | CA2 | |
| SCHEMBL4916810 | 0.78 | CA2 (0.37) | CA2 | |
| SCHEMBL4916804 | 0.78 | CA2 (0.37) | CA2 | |
| SCHEMBL4918012 | 0.78 | CA2 (0.37) | CA2 | |
| SCHEMBL3280990 | 0.78 | CA2 (0.36) | CA2 | |
| SCHEMBL29983676 | 0.77 | PDK1 (0.39) | CA2 | |
| SCHEMBL29984022 | 0.77 | PDK1 (0.39) | CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119215031-A | Arylaniline and heteroaryl aniline compounds for the treatment of skin cancer | 恩福莱克逊治疗有限公司 | 2024-12-31 | — | — | CN | disclosed |
| CN-113660931-B | Arylaniline and heteroaryl aniline compounds for the treatment of skin cancer | 恩福莱克逊治疗有限公司 | 2024-10-11 | — | — | CN | disclosed |
| CN-113645964-B | Arylaniline and heteroaryl aniline compounds for fetal treatment | 恩福莱克逊治疗有限公司 | 2024-10-11 | — | — | CN | disclosed |
| CN-117551073-A | Thienylaniline compounds for the treatment of dermatological disorders | 恩福莱克逊治疗有限公司 | 2024-02-13 | — | — | CN | disclosed |
| US-7078438-B2 | N-(4 substituted phenyl)-anthranilic acid hydroxamate esters | WARNER-LAMBERT COMPANY (US) | 2006-07-18 | — | — | US | disclosed |
| US-20050137263-A1 | N-(4 substituted phenyl)-anthranilic acid hydroxamate esters | WARNER-LAMBERT COMPANY, LLC | 2005-06-23 | — | — | US | disclosed |
| US-6891066-B2 | N-(4-substituted phenyl)-anthranilic acid hydroxamate esters | WARNER-LAMBERT COMPANY (US) | 2005-05-10 | — | — | US | disclosed |
| US-20040006245-A1 | N-(4-substituted phenyl)-anthranilic acid hydroxamate esters | REWCASTLE GORDON WILLIAM (NZ) | 2004-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137263-A1 | N-(4 substituted phenyl)-anthranilic acid hydroxamate esters | PAH, EGLN3, PAOX | CA2 311/4885 |
| US-20040006245-A1 | N-(4-substituted phenyl)-anthranilic acid hydroxamate esters | HCAR2, EGLN3, AADAC | CA2 288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.